These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 34500804)
1. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa. Kundu S; Wu S Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804 [TBL] [Abstract][Full Text] [Related]
2. Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa. Yoon HJ; Kundu S; Wu S Molecules; 2023 Oct; 28(19):. PubMed ID: 37836752 [TBL] [Abstract][Full Text] [Related]
3. Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa. Yang L; Rezaie AR J Biol Chem; 2013 May; 288(18):12692-8. PubMed ID: 23530052 [TBL] [Abstract][Full Text] [Related]
4. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. Hopfner KP; Brandstetter H; Karcher A; Kopetzki E; Huber R; Engh RA; Bode W EMBO J; 1997 Nov; 16(22):6626-35. PubMed ID: 9362477 [TBL] [Abstract][Full Text] [Related]
5. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317 [TBL] [Abstract][Full Text] [Related]
6. Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives. Gao JS; Tong XP; Chang YQ; He YX; Mei YD; Tan PH; Guo JL; Liao GC; Xiao GK; Chen WM; Zhou SF; Sun PH Drug Des Devel Ther; 2015; 9():1743-59. PubMed ID: 25848211 [TBL] [Abstract][Full Text] [Related]
7. Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study. Vadivel K; Schreuder HA; Liesum A; Schmidt AE; Goldsmith G; Bajaj SP J Thromb Haemost; 2019 Apr; 17(4):574-584. PubMed ID: 30725510 [TBL] [Abstract][Full Text] [Related]
9. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. Wang S; Beck R; Blench T; Burd A; Buxton S; Malic M; Ayele T; Shaikh S; Chahwala S; Chander C; Holland R; Merette S; Zhao L; Blackney M; Watts A J Med Chem; 2010 Feb; 53(4):1465-72. PubMed ID: 20121198 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in serine protease inhibitors as anticoagulant agents. Prezelj A; Anderluh PS; Peternel L; Urleb U Curr Pharm Des; 2007; 13(3):287-312. PubMed ID: 17313362 [TBL] [Abstract][Full Text] [Related]
11. Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa. Yang L; Manithody C; Qureshi SH; Rezaie AR J Biol Chem; 2010 Sep; 285(37):28488-95. PubMed ID: 20628058 [TBL] [Abstract][Full Text] [Related]
12. Discovery of FIXa inhibitors by combination of pharmacophore modeling, molecular docking, and 3D-QSAR modeling. Li P; Peng J; Zhou Y; Li Y; Liu X; Wang L; Zuo Z J Recept Signal Transduct Res; 2018 Jun; 38(3):213-224. PubMed ID: 29724133 [TBL] [Abstract][Full Text] [Related]
13. Development of a novel class of potent and selective FIXa inhibitors. Zhang T; Andre P; Bateman TJ; Chen YH; Desai K; Ellsworth K; Geissler WM; Guo L; Hruza A; Jian T; Meng D; Parker DL; Qian X; Reichert P; Sherer EC; Shu M; Smith CJ; Sonatore LM; Tschirret-Guth R; Nolting AF; Orr R; Campeau LC; Araki K; Nishimura T; Sakurada I; Wood HB Bioorg Med Chem Lett; 2015 Nov; 25(21):4945-4949. PubMed ID: 25978966 [TBL] [Abstract][Full Text] [Related]
14. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. Bhunia SS; Roy KK; Saxena AK J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063 [TBL] [Abstract][Full Text] [Related]
16. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors. Yang J; Su G; Ren Y; Chen Y Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810 [TBL] [Abstract][Full Text] [Related]
17. The first epidermal growth factor-like domains of factor Xa and factor IXa are important for the activation of the factor VII--tissue factor complex. Ndonwi M; Broze G; Bajaj SP J Thromb Haemost; 2005 Jan; 3(1):112-8. PubMed ID: 15634274 [TBL] [Abstract][Full Text] [Related]
18. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Zhu Y; Lin Y; Liu X; Hu W; Wang Y Biochem Biophys Res Commun; 2017 Jan; 483(1):495-501. PubMed ID: 28007598 [TBL] [Abstract][Full Text] [Related]
19. Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor. Heeb MJ; Cabral KM; Ruan L J Biol Chem; 2005 Oct; 280(40):33819-25. PubMed ID: 16093243 [TBL] [Abstract][Full Text] [Related]
20. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors. Wang S; Beck R; Burd A; Blench T; Marlin F; Ayele T; Buxton S; Dagostin C; Malic M; Joshi R; Barry J; Sajad M; Cheung C; Shaikh S; Chahwala S; Chander C; Baumgartner C; Holthoff HP; Murray E; Blackney M; Giddings A J Med Chem; 2010 Feb; 53(4):1473-82. PubMed ID: 20121197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]